The combination of ET with cyclin-dependent kinases 4/6 inhibitors (CDK4/6is) is the recommended first-line treatment for patients with HR + , human epidermal growth factor receptor-2–negative (HER2–) ABC, in the absence of visceral crisis [5, 6]. This evidence concerns the gene HR and aneurysmal bone cyst.